1. patients with a history of allergy or anaphylaxis to ingredients in isoquercetin (iqc-950an) including known intolerance of niacin or ascorbic acid or known glucose-6-phosphate dehydrogenase (g6pd) deficiency; 2. patients with known chronic kidney disease with estimated creatinine clearance \< 50 ml/minute or need for dialysis; 3. patients receiving an intensified dose regimen of low molecular weight heparin (lmwh) or unfractionated heparin (defined as doses of lmwh or unfractionated heparin greater than those approved for thromboprophylaxis) or dual antiplatelet therapy; 4. patients who are severely hypotensive defined as needing hemodynamic pressors to maintain blood pressure; 5. patients with moderate or severe thrombocytopenia (platelet count \<100 × 10⁹/l); 6. patients who are breast-feeding an infant or child; 7. patients who are pregnant or unwilling to use an appropriate form of contraception, except for heterosexual celibacy 8. any other condition that, in the opinion of the investigator, may adversely affect the patient's ability to complete this study or its measures, or pose a significant risk to the patient; 9. any reason the investigator suspects that data collected from this patient would be incomplete or of poor quality

1. patients with a history of allergy or anaphylaxis to ingredients in isoquercetin (iqc-950an) including known intolerance of niacin or ascorbic acid or known glucose-6-phosphate dehydrogenase (g6pd) deficiency; 2. patients with known chronic kidney disease with estimated creatinine clearance \< 50 ml/minute or need for dialysis; 3. patients receiving an intensified dose regimen of low molecular weight heparin (lmwh) or unfractionated heparin (defined as doses of lmwh or unfractionated heparin greater than those approved for thromboprophylaxis) or dual antiplatelet therapy; 4. patients who are severely hypotensive defined as needing hemodynamic pressors to maintain blood pressure; 5. patients with moderate or severe thrombocytopenia (platelet count \<100 × 10⁹/l); 6. patients who are breast-feeding an infant or child; 7. patients who are pregnant or unwilling to use an appropriate form of contraception, except for heterosexual celibacy 8. any other condition that, in the opinion of the investigator, may adversely affect the patient's ability to complete this study or its measures, or pose a significant risk to the patient; 9. any reason the investigator suspects that data collected from this patient would be incomplete or of poor quality

patients with a history of allergy or anaphylaxis to ingredients in isoquercetin (iqc-950an) including known intolerance of niacin or ascorbic acid or known glucose-6-phosphate dehydrogenase (g6pd) deficiency; patients with known chronic kidney disease with estimated creatinine clearance < 50 ml/minute or need for dialysis; patients receiving an intensified dose regimen of low molecular weight heparin (lmwh) or unfractionated heparin (defined as doses of lmwh or unfractionated heparin greater than those approved for thromboprophylaxis) or dual antiplatelet therapy; patients who are severely hypotensive defined as needing hemodynamic pressors to maintain blood pressure; patients with moderate or severe thrombocytopenia (platelet count <100 × 10⁹/l); patients who are breast-feeding an infant or child; patients who are pregnant or unwilling to use an appropriate form of contraception, except for heterosexual celibacy any other condition that, in the opinion of the investigator, may adversely affect the patient's ability to complete this study or its measures, or pose a significant risk to the patient; any reason the investigator suspects that data collected from this patient would be incomplete or of poor quality

patients with a history of allergy or anaphylaxis to ingredients in isoquercetin (iqc-950an) including known intolerance of niacin or ascorbic acid or known glucose-6-phosphate dehydrogenase (g6pd) deficiency; patients with known chronic kidney disease with estimated creatinine clearance < 50 ml/minute or need for dialysis; patients receiving an intensified dose regimen of low molecular weight heparin (lmwh) or unfractionated heparin (defined as doses of lmwh or unfractionated heparin greater than those approved for thromboprophylaxis) or dual antiplatelet therapy; patients who are severely hypotensive defined as needing hemodynamic pressors to maintain blood pressure; patients with moderate or severe thrombocytopenia (platelet count <100 × 10⁹/l); patients who are breast-feeding an infant or child; patients who are pregnant or unwilling to use an appropriate form of contraception, except for heterosexual celibacy any other condition that, in the opinion of the investigator, may adversely affect the patient's ability to complete this study or its measures, or pose a significant risk to the patient; any reason the investigator suspects that data collected from this patient would be incomplete or of poor quality

1. patients with a history of allergy or anaphylaxis to ingredients in isoquercetin (iqc-950an) including known intolerance of niacin or ascorbic acid or known glucose-6-phosphate dehydrogenase (g6pd) deficiency; 2. patients with known chronic kidney disease with estimated creatinine clearance < 50 ml/minute or need for dialysis; 3. patients receiving an intensified dose regimen of low molecular weight heparin (lmwh) or unfractionated heparin (defined as doses of lmwh or unfractionated heparin greater than those approved for thromboprophylaxis) or dual antiplatelet therapy; 4. patients who are severely hypotensive defined as needing hemodynamic pressors to maintain blood pressure; 5. patients with moderate or severe thrombocytopenia (platelet count <100 × 10⁹/l); 6. patients who are breast-feeding an infant or child; 7. patients who are pregnant or unwilling to use an appropriate form of contraception, except for heterosexual celibacy 8. any other condition that, in the opinion of the investigator, may adversely affect the patient's ability to complete this study or its measures, or pose a significant risk to the patient; 9. any reason the investigator suspects that data collected from this patient would be incomplete or of poor quality

1. patients with a history of allergy or anaphylaxis to ingredients in isoquercetin (iqc-950an) including known intolerance of niacin or ascorbic acid or known glucose-6-phosphate dehydrogenase (g6pd) deficiency; 2. patients with known chronic kidney disease with estimated creatinine clearance < 50 ml/minute or need for dialysis; 3. patients receiving an intensified dose regimen of low molecular weight heparin (lmwh) or unfractionated heparin (defined as doses of lmwh or unfractionated heparin greater than those approved for thromboprophylaxis) or dual antiplatelet therapy; 4. patients who are severely hypotensive defined as needing hemodynamic pressors to maintain blood pressure; 5. patients with moderate or severe thrombocytopenia (platelet count <100 × 10⁹/l); 6. patients who are breast-feeding an infant or child; 7. patients who are pregnant or unwilling to use an appropriate form of contraception, except for heterosexual celibacy 8. any other condition that, in the opinion of the investigator, may adversely affect the patient's ability to complete this study or its measures, or pose a significant risk to the patient; 9. any reason the investigator suspects that data collected from this patient would be incomplete or of poor quality

1. patients with a history of allergy or anaphylaxis to ingredients in isoquercetin (iqc-950an) including known intolerance of niacin or ascorbic acid or known glucose-6-phosphate dehydrogenase (g6pd) deficiency; 2. patients with known chronic kidney disease with estimated creatinine clearance < 50 ml/minute or need for dialysis; 3. patients receiving anticoagulant or antiplatelet medication, other than low dose aspirin; 4. patients who are severely hypotensive defined as needing hemodynamic pressors to maintain blood pressure; 5. patients with moderate or severe thrombocytopenia (platelet count <100 × 10⁹/l); 6. patients who are breast-feeding an infant or child; 7. patients who are pregnant or unwilling to use an appropriate form of contraception, except for heterosexual celibacy 8. any other condition that, in the opinion of the investigator, may adversely affect the patient's ability to complete this study or its measures, or pose a significant risk to the patient; 9. any reason the investigator suspects that data collected from this patient would be incomplete or of poor quality

1. patients with a history of allergy or anaphylaxis to ingredients in isoquercetin (iqc-950an) including known intolerance of niacin or ascorbic acid or known glucose-6-phosphate dehydrogenase (g6pd) deficiency; 2. patients with known chronic kidney disease with estimated creatinine clearance < 50 ml/minute or need for dialysis; 3. patients receiving anticoagulant or antiplatelet medication, other than low dose aspirin; 4. patients who are severely hypotensive defined as needing hemodynamic pressors to maintain blood pressure; 5. patients with moderate or severe thrombocytopenia (platelet count <100 × 10⁹/l); 6. patients who are breast-feeding an infant or child; 7. patients who are pregnant or unwilling to use an appropriate form of contraception, except for heterosexual celibacy 8. any other condition that, in the opinion of the investigator, may adversely affect the patient's ability to complete this study or its measures, or pose a significant risk to the patient; 9. any reason the investigator suspects that data collected from this patient would be incomplete or of poor quality